4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q1 EPS of ($0.88), $0.01 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $1.03 million.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.